Skip to main content

Krishnan Suma's Form 4 filing

Krystal Biotech, Inc. (KRYS) · filed Jul 16, 2025

Accession no.
0001298711-25-000009
Filed
Jul 16, 2025
Trade date
Jul 14-16, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 9 non-derivative transactions. Open-market sales total $5.39M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Krishnan SumaCIK 0001298711Director, Officer (President, R&D), 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 14, 2025Common StockSSaleDisposed−13,335$150.29F2−$2,004,117.151,443,376DirectDuplicate filing
Jul 14, 2025Common StockSSaleDisposed−100$151.00F3−$15,1001,443,276DirectDuplicate filing
Jul 15, 2025Common StockSSaleDisposed−2,236$150.68F4−$336,920.481,441,040DirectDuplicate filing
Jul 15, 2025Common StockSSaleDisposed−800$151.79F3−$121,4321,440,240DirectDuplicate filing
Jul 16, 2025Common StockSSaleDisposed−1,529$150.00F3−$229,3501,438,711DirectDuplicate filing
Jul 14, 2025Common StockSSaleDisposed−13,400$150.30F7−$2,014,0201,512,529IndirectDuplicate filing
Jul 15, 2025Common StockSSaleDisposed−2,184$150.68F9−$329,085.121,510,345IndirectDuplicate filing
Jul 15, 2025Common StockSSaleDisposed−900$151.79F3−$136,6111,509,445IndirectDuplicate filing
Jul 16, 2025Common StockSSaleDisposed−1,389$150.00F3−$208,3501,508,056IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The transaction was executed in multiple trades ranging from $150.00 to $150.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

F3

The transaction was executed in one trade.

Referenced by the price of 5 transactions in Table I.

F4

The transaction was executed in multiple trades ranging from $150.21 to $151.18. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

F7

The transaction was executed in multiple trades ranging from $150.00 to $150.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

F9

The transaction was executed in multiple trades ranging from $150.21 to $151.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)